Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025

Some of the top podcast episodes of 2025 included live takeaways on the hottest conference data to intimate conversations regarding the psychosocial side of oncologic care.

It was another busy year for podcasts on CancerNetwork®, as 2025 saw continued collaboration with experts in several different specialties to provide critical in-depth perspectives from all corners of the oncology world. Between the community genitourinary oncology issues explored on Oncology Decoded and psycho-oncology talks organized with the help of the American Psychosocial Oncology Society, these discussions have represented voices across the cancer care continuum.

Some of the top podcast episodes of 2025 included live takeaways on the hottest conference data to intimate conversations regarding the psychosocial side of oncologic care. Here are the top 10 Oncology On the Go episodes that listeners tuned in to throughout 2025.

#1: Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

As part of a series of discussions, Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, spoke about the clinical trial results, administration protocols, and adverse effect (AE) management strategies related to the use of tarlatamab-dlle (Imdelltra) for patients with small cell lung cancer (SCLC). The group detailed supporting efficacy data from studies like the phase 2 DeLLphi-301 trial (NCT05060016) as well as the implications of the FDA’s approval of tarlatamab for patients with extensive-stage SCLC in May 2024.1

Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital.

#2: Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

In a recap of the lung cancer portion of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephen Liu, MD, and Joshua Sabari, MD, discussed the most practice-changing data across different lung cancer presentations as part of a live X Spaces discussion.

Liu, an associate professor of medicine at Georgetown University and the director of thoracic oncology and head of developmental therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Sabari, an assistant professor in the Department of Medicine at the New York University Grossman School of Medicine and the director of high reliability organization initiatives at the Perlmutter Cancer Center, highlighted how results from studies like the phase 3 DeLLphi-304 trial (NCT05740566) may shape the lung cancer paradigm.2

#3: Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

At the 5-year anniversary of the COVID-19 pandemic, several expert clinicians and researchers reflected on how COVID-19 impacted their work in oncology in the long term. These guests included:

1. Aditya Bardia, MD, MPH, FASCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at the University of California Los Angeles Health Jonsson Comprehensive Cancer Center;
2. Ritu Salani, MD, director of Gynecologic Oncology at the University of California Los Angeles, and ONCOLOGY® editorial advisory board member;
3. Scarlett Lin Gomez, PhD, MPH, a professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco (UCSF), and co-leader of the Cancer Control Program at UCSF Helen Diller Family Comprehensive Cancer Center
4. Marwan F. Fakih, MD, professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope Comprehensive Cancer Center;
5. Elizabeth Zhang-Velten, MD, a radiation oncologist at Keck Medicine of University of Southern California;
6. Frances Elaine Chow, MD, neuro-oncologist at the University of Southern California (USC) Norris Comprehensive Cancer Center;
7. James B. Yu, MD, MHS, FASTRO, assistant professor adjunct, Department of Radiation Oncology, Smilow Cancer Hospital at Saint Francis Hospital, and ONCOLOGY editorial advisory board member.

#4: Navigating Management and Dosing Considerations for Amivantamab in NSCLC

In another edition of their podcast series, Daniel Morgensztern, Mary Ellen Flanagan, and Janelle Mann detailed key clinical trial data and considerations for administering amivantamab-vmjw (Rybrevant) to patients with EGFR-mutated non–small cell lung cancer (NSCLC). After an overview of amivantamab’s mechanism of action from Morgensztern, Mann reviewed key dosing strategies as patients receive the therapy via intravenous infusion. Additionally, Flanagan discussed considerations for mitigating the risk of venous thromboembolism, cutaneous toxicities, and other AEs.

#5: How to Discuss Death: A Conversation of Mortality in Cancer Care

In an episode created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, welcomed William S. Breitbart, MD, to explore how clinicians can address the existential concerns of patients with cancer. Their conversation touched upon mitigating feelings of fear, uncertainty, and depression surrounding the possibility of death among patients undergoing treatment for their disease.

McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY. Breitbart is an attending physician and the Jimmie C. Holland Chair in Psycho-Oncology at Memorial Sloan Kettering Cancer Center.

#6: Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH, cardiology fellow at Weill Cornell Medicine, spoke about a manuscript he coauthored in the June 2025 issue of ONCOLOGY titled “Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.” He discussed noteworthy cardiotoxicities associated with specific classes of breast cancer therapies while outlining additional next steps for enhancing cardiovascular outcomes for those with breast cancer.

#7: Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

In a cobranded episode produced in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The discussion particularly focused on the use of lifileucel (Amtagvi) for those with unresectable or metastatic melanoma.

The panel consisted of Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky Markey Cancer Center in Lexington.

#8: Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

In partnership with the Foundation for Women’s Cancer, CancerNetwork spoke with Kathleen N. Moore, MD, MS, about distinguishing low grade serous ovarian cancer from other types of disease, therapeutic options in younger patients seeking to preserve fertility, and other critical developments in the field. The discussion touched upon first-line standards of care as well as multiple trials evaluating novel regimens, particularly those including the use of letrozole (Femara).

Moore is the Virginia Kerley Cade Endowed Chair of Cancer Development, associate director of Clinical Research at the Stephenson Cancer Center, director of the Oklahoma TSET Phase I Program and professor in the Section of Gynecologic Oncology the University of Oklahoma Health Sciences Center.

#9: Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

In an episode produced in collaboration with ASTCT, Rahul Banerjee, MD, FACP, spoke with Shernan Holtan, MD, as part of a live X Spaces discussion recapping the most notable abstracts to emerge from the 2025 Tandem Meeting. The pair reviewed several oral presentations and poster pieces on novel CAR T-cell therapies and transplantation strategies across lymphoma, multiple myeloma, and other hematologic malignancies.

Banerjee is an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Holtan is the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.

#10: Man Up? The Truth About Men's Health After Cancer

In another episode created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, convened with Christian J. Nelson, PhD, to highlight sexual health issues for men after cancer treatment, especially in the case of genitourinary malignancies like prostate and testicular cancer.

Nelson, chief of Psychiatry Service, attending psychologist, and codirector of the Psycho-Oncology of Care and Aging Program at Memorial Sloan Kettering Cancer Center, detailed how therapies for prostate cancer and other malignancies may cause AEs that negatively impact a man’s sense of self and masculinity. The pair also touched upon the need for clinicians to proactively normalize discussions about sexual health, which may inform patients of standard and expected aspects of the cancer experience.

References

1. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. News release. FDA. May 16, 2024. Accessed December 19, 2025. https://tinyurl.com/48k34rw5
2. Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of ph3 DeLLphi-304. J Clin Oncol. 2025;43(suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008